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Background: The present study sought to investigate erythrocyte glutathione S-transferases (GST),
NADH-Methaemoglobin reductase (NADH-MR) and Na+/K+-ATPase activities of hypoglycemic rats treated with
ethanol/water (1:2 v/v) extract of A. sativa as agent of glycemic control.
Methods: Hyperglycemia was induced by a single intra-peritoneal injection of 0.1 mol/L alloxan monohydrate in
phosphate buffer saline (PBS) solution (pH = 7.4); dosage = 140 mg/kg. At the end of the experimental time
(t = 76 h), erythrocyte GST, NADH-MR and Na+/K+-ATPase activities as well as serum fasting blood sugar (FBS)
levels were measured by spectrophotometric methods.
Results: Serum FBS levels of control/normal (C/N) rats ranged between 72.93 ± 0.82–95.12 ± 0.92 mg/dL, whereas
experimental rats without glycemic control gave: 249.41 ± 1.03–256.11 ± 1.23 mg/dL. Hyperglycemic rats treated
with ethanol/water (1:2 v/v) extract of A. sativa exhibited comparative reduced serum levels of FBS alongside with
erythrocyte GST, NADH-MR and Na+/K+-ATPase activities. The average relative activities of the three enzymes and
corresponding order of enzyme activity in hyperglycemic rats treated with ethanol/water (1:2 v/v) extract of A. sativa
was: NADH-MR = 60.99% > GST = 47.81% > Na+/K+-ATPase = 46.81%. In the same order, relative activities of the three
enzymes in rats without glycemic control were: NADH-MR = 49.65% > GST = 23.69% > Na+/K+-ATPase = 17.02%.
Conclusion: Erythrocyte GST, NADH-MR and Na+/K+-ATPase activities gave insights into the pathophysiology of
diabetic state and served as biomarkers for ascertaining therapeutic control in Type 1 diabetes mellitus.
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Diabetes mellitusIntroduction
Diabetic mellitus is an endocrine disorder character-
ized by insufficiency in circulating plasma level of in-
sulin (Type 1, or Insulin-Dependent Diabetes Mellitus;
IDDM) and peripheral resistance and insensitivity to
insulin (Type 2, or Non-Insulin-Dependent Diabetes
Mellitus; NIDDM). Unlike Type 1 diabetes mellitus,
Type 2 is associated with hyperinsulinism. Primarily,
overall physiologic distortions prompted by poor con-
trol of metabolism in absence or insufficiency of insu-
lin engender hyperglycemia and associated metabolic
disorders [1,2]. Striking consequential effects of prolong* Correspondence: p_chikezie@yahoo.com
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article, unless otherwise stated.hyperglycemia are changes in structure and function of
macromolecules [3,4], auto-oxidation of glycated pro-
teins, increased production of reactive oxygen species
(ROS), decreased antioxidant defense, increased lipid
peroxidation, and associated apoptosis or necrosis occa-
sioned by membrane degeneration [4,5]. Notably, alter-
ations/adjustments in most glycolytic, tricarboxylic acid
cycle (TCA) enzymes activities are associated with dia-
betic states [5,6]. Activities of these enzymes (pyruvate
kinase, pyruvate dehydrogenase, glycogen synthase, pyru-
vate carboxylase, fructose 1, 6-bisphosphate etc.) are regu-
lated by insulin and have been observed to be
phosphoenzymes. Activation of enzyme activity in re-
sponse to insulin stimulus is prompted by cyclic adenosine
monophosphate (cAMP) phosphodiesterase mediatedd Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Chikezie and Uwakwe Journal of Diabetes & Metabolic Disorders 2014, 13:50 Page 2 of 9
http://www.jdmdonline.com/content/13/1/50pathway [6] or through secondary metabolic events con-
nected to insulin action.
Glutathione S-transferases (GSTs) are multi-gene and
multifunctional antioxidant enzymes that comprise sev-
eral classes of GST isozymes. These enzymes by virtue
of their activities act as subset of numerous cellular anti-
oxidants defense systems against ROS species that are as-
sociated with many disease-causing electrophiles [2,7,8].
NADH-Methaemoglobin reductase (NADH-MR) (EC:
1.6.2.2) transfers electrons from NADH + H+ to cyto-
chrome b5 via its flavin adenine dinucleotide (FAD) pros-
thetic group [9]. This erythrocyte enzyme maintains
hemoglobin in its ferrous (Fe2+) state [10]. Na+/K+-ATPase,
also called the sodium pump, is a soluble conserved tri-
meric pump (α-133 kDa; β-35 kDa; γ-10 kDa) involved in
transmembrane cation regulation via ATP–dependent dual
efflux/influx of sodium (Na+) and potassium (K+) ions in
various cells [11,12]. The regulation of this pump activity is
dependent on the phosphorylation of the α-subunit of
Na+/K+-ATPase [11,13].
Allium sativa has been widely reported to exhibit
therapeutic benefits to numerous pathologic states whose
etiology is linked to oxidative stressors and electrophiles
[14] such as diabetes mellitus [15-18], atherosclerosis
[19,20], hyperlipidemia [20,21] thrombosis [22], hyper-
tension [23]. Phytochemical and biochemical profile
of A. sativa has been reported elsewhere [24]. The
present study was based on the premise that hypergly-
cemia is one of the various indicators and promoters of
distortional haemostasis associated with diabetes mellitus.
Therefore, we sought to investigate level of alterations in
erythrocyte GST, NADH-MR and Na+/K+-ATPase ac-
tivities of hypoglycemic rats treated with ethanol/water
(1:2 v/v) extract of A. sativa as agent of glycemic control.
Materials and methods
Collection of plant specimen
Fresh samples of A. sativa were obtained in July, 2012
from local market at Umoziri-Inyishi, Imo State, Nigeria.
The plant specimen was identified and authenticated by
Dr. F.N. Mbagwu at the Herbarium of the Department
of Plant Science and Biotechnology, Imo State University,
Owerri, Nigeria. A voucher specimen was deposited at the
Herbarium for reference purposes.
Preparation of extract
Fresh bulbs of A. sativa were washed under a continu-
ous stream of distilled water for 15 min and air-dried
at room temperature for 5 h. The bulbs were chopped
and further dried for 5 h in an oven at 60°C and sub-
sequently ground with a ceramic mortar and pestle.
Twenty-five grams (25 g) of pulverized specimen was
suspended in 250 mL of ethanol/water mixture (1:2 v/v)
in stoppered flasks and allowed to stand at −4°C for 24 h.The suspensions were filtered with Whatman No. 24 fil-
ter papers. The filtrate was concentrated in a rotary evap-
orator at 50°C and dried in vacuum desiccator. The yield
was calculated to be 3.4% (w/w). The extract was finally
suspended in phosphate buffered saline (PBS) solution
(extract vehicle), osmotically equivalent to 100 g/L PBS
(90.0 g NaCI, 17.0 Na2HPO4.2H2O and 2.43 g NaH2-
PO4.2H2O), and used in all the studies with doses
expressed in mg/kg of body weight of the animals.
Experimental animals
Male rats Rattus norvegicus (8–10 weeks old) weighing
150–200 g were generous gift from Professor A.A. Uwakwe
(Department of Biochemistry, University of Port Harcourt,
Nigeria). The rats were maintained at room temperatures
of 25 ± 5°C, 30–55% of relative humidity on a 12-h light/
12-h dark cycle, with access to water and food ad libitum
for 2 weeks acclimatization period. The handling of the an-
imals was in accordance with the standard principles of
laboratory animal care of the United States National Insti-
tutes of Health (NIH, 1978).
Induction of hyperglycemia and study design
Hyperglycemia was induced by a single intra-peritoneal
injection of 0.1 mol/L alloxan monohydrate in PBS solu-
tion (pH = 7.4) at a dosage of 140 mg/kg. The animals
were considered hyperglycemic when their blood glu-
cose concentrations exceeded 250 mg/dL 72 h after al-
loxan treatment, which was in conformity with our
previous study [24]. The animals were deprived of food
and water for additional 16 h before commencement of
treatment (control and test experiments) as described
elsewhere [24].
A total of twenty four (24) rats were divided into six (6)
groups of four (n = 4) each as follows:
 Group C1; Control-Normal (C/N): Normal rats
received only PBS (Vehicle; 1.0 mL/kg/16 h, i. p.)
for 64 h.
 Group C2; Control-Hyperglycemic (C/H): Hypergly-
cemic rats received PBS (Vehicle; 1.0 mL/kg/16 h, i. p.)
for 64 h.
 Group T1; H[A. sativa] = 1.0 mg/kg: Hyperglycemic rats
received A. sativa (1.0 mg/kg/16 h, i. p.) for 64 h.
 Group T2; H[A. sativa] = 2.0 mg/kg: Hyperglycemic rats
received A. sativa (2.0 mg/kg/16 h, i. p.) for 64 h.
 Group T3; H[A. sativa] = 4.0 mg/kg: Hyperglycemic rats
received A. sativa (4.0 mg/kg/16 h, i. p.) for 64 h.
 Group T5; H[Glibenclamide] = 5.0 mg/kg: Hyperglycemic rats
received glibenclamide (5.0 mg/kg/16 h, i. p.) for 64 h.
Measurement of fasting blood sugar
After alloxan treatment, blood samples were drawn from
apical region of the tails of the rats i.e., at experimental
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t = 76 h for measurement of fasting blood sugar (FBS).
Determination of serum level of FBS was by glucose
oxidase method according to the Randox® kit manufac-
turer’s procedure (Randox® Laboratories Ltd. Ardmore,
United Kingdom). Glibenclamide, a standard anti-diabetic
agent is a product of Aventis Pharma. Ltd. Goa, India.
Collection of blood and preparation of erythrocyte
haemolysate
At the end of treatment, the animals were fasted for
12 h [15] and subsequently sacrificed according to
United States National Institutes of Health approved
protocols (NIH, 1978). Blood volume of 4.0 mL was ob-
tained by carotid artery puncture using hypodermic syr-
inge. The erythrocytes were separated from plasma by
bench centrifugation for 10 min. The harvested erythro-
cytes were washed by methods of Tsakiris et al., [25]
as described by Chikezie et al., [26]. Within 2 h of col-
lection of blood specimen, 1.0 mL of harvested erythrocyte
was introduced into centrifuge test tubes containing
3.0 mL of buffer solution pH = 7.4: 250 mM tris (hydroxyl
methyl) amino ethane–HCl (Tris–HCl)/140 mM NaCl/
1.0 mM MgCl2/10 mM glucose). The erythrocytes sus-
pension was further centrifuged at 1200 g for 10 min and
repeated 3 times. According to Chikezie [27], to remove
platelets and leucocytes, the pellet was re-suspended in
3.0 mL of phosphate-buffered saline (PBS) solution
(pH = 7.4) and passed through a column (3.5 cm in a
30 mL syringe) of cellulose-microcrystalline cellulose (ratio
w/w 1:1) [28]. The eluted fraction was passed twice
through a new column of cellulose-microcrystalline cel-
lulose (ratio 1:1 w/w) to obtain erythrocyte suspension
sufficiently devoid of leucocytes and platelets. Finally,
erythrocytes were re-suspended in 1.0 mL of this buffer
and stored at 4°C. The washed erythrocytes were lysed by
freezing/thawing as described by Galbraith and Watts,
[29] and Kamber et al., [30]. The erythrocyte haemolysate
was used for the determination of erythrocyte glutathione
S-transferase (GST) and NADH-Methaemoglobin reduc-
tase (NADH-MR) activity.
Erythrocyte haemolysate haemoglobin concentration
The cyanomethaemoglobin reaction modified method
of Baure, [31] as described by Chikezie et al., [26] was
used for measurement of haemolysate haemoglobin
concentration. A 0.05 mL portion of erythrocyte hae-
molysate was added to 4.95 mL of Drabkins reagent
(100 mg NaCN and 300 mg K4Fe(CN)6 per liter). The
mixture was left to stand for 10 min at 25 ± 5°C and
absorbance read at λmax = 540 nm against a blank. The
absorbance was used to evaluate for haemolysate haemo-
globin concentration by comparing the values with the
standard.Erythrocyte glutathione S-transferase
GST activity was measured by the method of Habig, [32]
as described by Pasupathi et al., [3] with minor modifi-
cations according to Chikezie et al., [26]. The reaction
mixture contained 1.0 mL of 0.3 mM phosphate buffer
(pH= 6.5), 0.1 mL of 30 mM 1-chloro-2, 4-dinitrobenzene
(CDNB) and 1.7 mL of distilled water. After pre-incubating
the reaction mixture at 37°C for 5 min, the reaction was
started by the addition of 0.1 mL of erythrocyte haemoly-
sate and 0.1 mL of glutathione (GSH) as substrate. The ab-
sorbance was followed for 5 min at λmax = 340 nm. The
enzyme activity was expressed as erythrocyte GST activity
in international unit per gram haemoglobin (IU/gHb) using
an extinction coefficient (∑) of 9.6 mM−1 cm−1 in reaction
in which 1 mole of GSH is oxidized (Eq. 1).
Erythrocyte NADH-Methaemoglobin reductase
NADH-MR activity was assayed according to the method
of Board, [33]. A mixture of 0.2 mLTris–HCl/EDTA buffer
pH = 8.0, 0.2 mL NADH and 4.35 mL of distilled water
was introduced into a test tube and incubated for 10 min
at 30°C. The content was transferred into a cuvette and the
reaction started by adding 0.2 mL of K3Fe(CN)6/0.05 mL
erythrocyte haemolysate. The increase in absorbance of the
medium was measured at λmax = 340 nm per min for
10 min at 30°C against a blank solution. NADH-MR
activity was expressed in international unit per gram
haemoglobin (IU/gHb) using an extinction coefficient
(∑) of 6.22 mM−1 cm−1 in reaction in which 1 mole of
NADH +H+ is oxidized (Eq. 1).
Calculation of GST and NADH-MR activities:







EA = Enzyme activity in IU/gHb
[Hb] = Haemolysate haemoglobin concentration (g/dL)
0. D/min = Change per min in absorbance at 340 nm.
VC = Cuvette volume (total assay volume) = 1.0 mL.
VH = Volume of haemolysate in the reaction system
(0.05 mL).
Erythrocyte ghost membrane preparation
A simplified procedure of DeLuise and Flier, [34] as re-
ported by Iwalokun and Iwalokun, [35] was used for
erythrocyte ghost membrane preparation. Briefly, 10 mL
of ice cold 5 mM Tris/0.1 mM Na2EDTA (pH = 7.6)
were added to test tubes containing buffy coat free–
packed erythrocytes of test and control rats to achieve
osmotic lysis. The resulting membranes were centrifuged
at 20,000 g for 20 min at 4°C. The membrane suspensions
Table 1 Serum FBS levels of hyperglycemic rats
with/without glycemic control
[FBS] mg/dL
Group t = 0 h t = 76 h
C/N 95.12 ± 0.92a 72.93 ± 0.82a
C/H 256.11 ± 1.23b 249.41 ± 1.03b
H[A. sativa] = 1.0 mg/kg 255.64 ± 1.09
b,c 125.11 ± 0.91c
H[A. sativa] = 2.0 mg/kg 261.13 ± 2.00
b,c,d 129.32 ± 1.50c,d
H[A. sativa] = 4.0 mg/kg 267.94 ± 0.92
c,d,e 132.61 ± 0.81d,e
H[Glibenclamide] = 5.0 mg/kg 265.49 ± 49
c,d,e,f 101.12 ± 0.80f
Means in the column with the same letters are not significantly different at
p > 0.05 according to LSD.
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pH = 7.6 and 3 times with 10 mM Tris–HCl (pH = 7.5).
The haemoglobin-free membrane suspension was finally
stored at −20°C in 10 mM Tris–HCl buffer (pH = 7.5).
Erythrocyte Na+/K+-ATPase
The erythrocyte total ATPase activity was determined
by incubating 50 μL of ghost membrane suspension
(~200 μg of membrane protein) of test and control rats
with 5 mM Tris-ATP, 25 mM KCl, 75 mM NaCl, 5 mM
MgCl2, 0.1 mM EDTA, 25 mM Tris–HCl (pH = 7.5) in
500 μL for 90 min at 37°C in a shaking water bath. The
reaction was stopped by adding tricarboxylic acid (TCA)
to a final concentration of 5% (w/v). After centrifugation
for 20 min at 1,500 g, an aliquot of the supernatant was
used to measure total inorganic phosphate liberated ac-
cording to Fiske and Subbarow, [36] reaction. This assay
was repeated in the presence of 200 μM methyldigoxin,
an inhibitor of Na+/K+-ATPase activity. Total ATPase
activity was expressed as micromole of inorganic phos-
phate liberated per milligram membrane protein per hour
(μM pi/mg protein/h). The activity of Na+/K+-ATPase was
subsequently determined by subtracting total ATPase ac-
tivity in the presence of digoxin from enzyme activity in
the absence of the inhibitor drug.
Ghost erythrocyte membrane protein
Membrane protein was measured according to the method
of Lowry et al., [37] after solubilizing aliquots of ghost
membrane suspension with 0.2% sodium dodecyl sulfate
(SDS). Bovine serum albumin (BSA) (50–300 μg), product
of Sigma Chemical Company, Saint Louis, Missouri, USA,
was used as standard. Absorbance was measured with
Beckmann D700 spectrophotometer (Beckmann, USA) at
λmax = 720 nm.
Statistical analyses
The data collected were analyzed by the analysis of vari-
ance procedure while treatment means were separated
by the least significance difference (LSD) incorporated in
the statistical analysis system (SAS) package of 9.1 ver-
sion (2006). The correlation coefficients between the re-
sults were determined with Microsoft Office Excel, 2010
version.
Results and discussion
Table 1 showed that serum FBS levels of C/N rats ranged
between 72.93 ± 0.82–95.12 ± 0.92 mg/dL, whereas the
experimental rats without glycemic control (C/H) was
between 249.41 ± 1.03–256.11 ± 1.23 mg/dL. These values
represented decrease in serum FBS levels by 22.19 mg/dL
and 6.7 mg/dL in C/N and C/H rats respectively within the
experimental time of 76 h. At experimental time t = 0 h
and t = 76 h, serum FBS levels of C/H was significantly(p < 0.05) higher than C/N rats. A cursory look at Table 1
showed that hyperglycemic rats treated with ethanol/
water (1:2 v/v) extract of A. sativa exhibited com-
parative reduced serum levels of FBS, which was in a
dose dependent manner. Serum FBS levels of hypergly-
cemic rats at t = 0 h was within the range of 255.64 ± 1.09–
267.94 ± 0.92 mg/dL.
However, these values represented marginal varia-
tions in serum FBS levels amongst the three categories
of A. sativa treated hyperglycemic rats (Group T1,
Group T2 and Group T3) within the experimental
time: 0 h ≤ t ≤ 76 h. Specifically, at t = 76 h, serum
FBS[A. sativa] = 1.0 mg/kg = 125 ± 0.91 mg/dL; FBS[A. sativa] =
2.0 mg/kg = 129.32 ± 1.50 mg/dL and FBS[A. sativa] = 4.0
mg/kg = 132.61 ± 0.81 mg/dL.; p < 0.05 compared to C/N
rats. Furthermore, t = 76 h, the three groups of A. sativa
treated hyperglycemic rats exhibited: H[A. sativa] = 1.0
mg/kg = 51.06%, H[A. sativa] = 2.0 mg/kg = 50.48% and H
[A. sativa] = 4.0 mg/kg = 50.41% reduction in serum FBS
levels compared to their corresponding FBS levels at
t = 0 h. Similarly, compared to serum FBS levels at t = 0 h,
H[Glibenclamide] = 5.0 mg/kg rats showed reduced serum FBS
level by 61.91% at t = 76 h, representing a ratio of 1: 1.4 de-
crease in serum FBS levels compared to C/N rats; p < 0.05.
At the end of the experiment, serum FBS levels of H
[A. sativa] = 1.0 mg/kg was not significantly different (p > 0.05)
from H[A. sativa] = 2.0 mg/kg rats. Likewise, FBS levels of H
[A. sativa] = 2.0 mg/kg showed no significantly difference
(p > 0.05) compared to H[A. sativa] = 4.0 mg/kg rats.
Within the experimental time, hyperglycemic rats with
or without glycemic control exhibited decreased levels of
erythrocyte GST activity. Specifically, erythrocyte GST
activity of C/H rats represented 23.69% of GST activity
of C/N rats (p < 0.05). Figure 1 showed a corresponding
increase in erythrocyte GST activity of hyperglycemic
rats treated with ethanol/water (1:2 v/v) extract of A. sativa
in a dose dependent manner (H[A. sativa] = 1.0–4.0 mg/kg) with
comparative no significant difference (p > 0.05). Further-
more, within the experimental time, the decreased levels of

























Figure 1 Erythrocyte GST activity of hyperglycemic rats with/without glycemic control.
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(1:2 v/v) extract of A. sativa were significantly differ-
ent (p < 0.05) from that of C/N rats. Also, erythrocyte
of H[Glibenclamide] = 5.0 mg/kg rats showed 76.82% GST
activity compared to the C/N rats (p < 0.05).
Figure 2 showed that erythrocyte NADH-MR activity
of rats without glycemic control (C/H rats) was not sig-
nificantly different (p > 0.05) from those with glycemic
control (H[A. sativa] = 1.0–4.0 mg/kg and H[Glibenclamide] = 5.0
mg/kg rats). Similarly, erythrocyte NADH-MR activity of
H[A. sativa] = 1.0–4.0 mg/kg rats was not significantly differ-
ent (p > 0.05) from H[Glibenclamide] = 5.0 mg/kg rats. Specif-
ically, erythrocyte NADH-MR activity of H[Glibenclamide] =



























Figure 2 Erythrocyte NADH-MR activity of hyperglycemic rats with/wNADH-MR activity of C/N rats, whereas H[A. sativa] =
1.0–4.0 mg/kg rats NADH-MR activity showed relative en-
zyme activity between the range of 49.65–63.12%.
Erythrocyte NADH-MR activity of C/H rats was signifi-
cantly (p < 0.05) lower than C/N rats, representing
68.97% reduction of NADH-MR activity in C/H rats.
Erythrocyte Na+/K+-ATPase activity of C/H rats was
reduced by 82.98% compared to C/N rats (p < 0.05). At
experimental t = 76 h, erythrocyte Na+/K+-ATPase ac-
tivity H[A. sativa] = 1.0–4.0 mg/kg rats showed progressive
increase in relative enzyme activity: H[A. sativa] = 1.0
mg/kg = 34.04%, H[A. sativa] = 2.0 mg/kg = 52.13% and H
[A. sativa] = 4.0 mg/kg = 54.26%. H[Glibenclamide] = 5.0 mg/kg
rats was 74.47% (Figure 3). An overview of Figures 1,0.87 0.89 0.95
ithout glycemic control.
































Figure 3 Erythrocyte Na+/K+-ATPase activity of hyperglycemic rats with/without glycemic control.
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three enzymes and corresponding order of enzyme activity
in hyperglycemic rats treated with ethanol/water (1:2 v/v)
extract of A. sativa was: NADH-MR= 60.99% >GST =
47.81% >Na+/K+-ATPase = 46.81%. In the same order, rela-
tive activities of the three enzymes in rats without glycemic
control were: NADH-MR = 49.65% > GST = 23.69% >
Na+/K+-ATPase = 17.02%. Furthermore, percentage de-
creases in GST, NADH-MR and Na+/K+-ATPase activ-
ities in H[A. sativa] = 1.0–4.0 mg/kg rats was related to the
capacity of ethanol/water (1:2 v/v) extract of A. sativa to
exert dose dependent glycemic control.
The use of experimental animal model for study of Type
1 diabetes mellitus has been widely reported [38-41]. The
cytotoxic action of diabetogenic agents is mediated by for-
mation of superoxide radicals and other related ROS,
causing massive destruction of the β-cells [39,42,43]. From
the present study, experimental rats treated with the
widely used diabetogenic agent–alloxan, in conformity
with previous reports elsewhere [24,39,42,43], showed evi-
dence of hyperglycemia (Table 1). Hyperglycemia is the
earliest and primary clinical presentation in diabetic states
[3,44]. Studies on the application of nutraceuticals,
sourced from spices and other edible plants and their
products, for the treatment and management of diabetes
mellitus have received the attention of several research
endeavours [45]. The present study showed evidence of
the capacity of ethanol/water extract of A. sativa to re-
duce serum level of FBS in hyperglycemic rats, which
compared fairly with the standard anti-diabetic drug-
glibenclamide (Table 1). The anti-diabetic properties of
A. sativa extract have been previously reported [15,24].
The therapeutic action of A. sativa as it applies to itsrole in the treatment and management of diabetes
mellitus is identical to the mode of action of other nu-
merous anti-diabetic agents of plant origin such as
Coriandrum sativum [45]; Gongronema latifolium [46];
Allium cepa Linn [15]. However, other mechanism of
therapeutic action, which involves increase peripheral
glucose consumption induced by Eugenia Floccosa [47],
Berberis lyceum [48] and Tinospora cordifolia roots [49]
have been documented. The active principles of these
plant extracts exhibited insulin-like effect by mimicry.
However, within the experimental time, administration
of the three experimental doses of ethanol/water (1:2 v/v)
extract of A. sativa as an instrument of glycemic con-
trol did not restore normal serum level of FBS (72.93 ±
0.82–95.12 ± 0.92 mg/dL) in hyperglycemic rats with
[FBS] > 250 mg/dL.
According to Raza et al., [5] oxidative stress is an
important factor in the etiology and pathogenesis of
diabetes mellitus. Furthermore, Pasupathi et al., [3] had
observed significant (p < 0.001) decrease in reduced gluta-
thione (GSH) concentration in diabetic erythrocytes com-
pared to control participants. They further averred that
decreased level of GSH was an aftereffect of increased
utilization of the coenzyme for scavenging ROS due to
elevated oxidative stress associated with diabetes. Conse-
quently, we observed decreased levels of erythrocyte
GST activity in hyperglycemic rats, which was in con-
formity with previous studies [3,44,45,50-52], since the
co-substrate (GSH) required for GST antioxidant pro-
tective activity [1,53] may have been utilized for other non-
enzymatic reductive pathways. Judging from erythrocyte
GST activity of rats without glycemic control, the relatively
higher levels of erythrocyte GST activity of hyperglycemic
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pattern (Figure 1) was an obvious indication of the cap-
ability of ethanolic extract of plant extract to serve as
anti-diabetic agent, fairly comparable to the standard
anti-diabetic drug-glibenclamide. Erythrocyte GST activ-
ity has been proven to be a reliable biochemical index
and basis for diagnosis and monitoring of therapeutic
events in the course of treatment and management of
other pathologic/metabolic disorders whose etiologies
and manifestations are linked to oxidative stress. Not-
able among which are: parasitic infections [26,54], gout
and rheumatoid arthritis [55,56], haemoglobinopathies
[26], malignancy [57], hypertension [58], stroke [59]
and atherosclerosis [60]. In a related perspective, Moasser
et al., [2] had previously given account of the use of GST
activity as a reliable biomarker in depicting the etiology of
diabetes mellitus. They posited that two isoforms of GST
(GSTM1 and GSTT1) might be involved in the pathogen-
esis of Type 2 diabetes mellitus in South Iranian popula-
tion. In addition, investigations by Yalin et al., [7] showed
that the GSTM1 gene may play a significant role in the
aetiopathogeneses of diabetes mellitus and could serve as
a useful biomarker in the prediction of diabetes mellitus
susceptibility of the Turkish population.
According to Coleman, [61] poor glycemic control in
diabetes and combination of oxidative, metabolic, and
carbonyl stresses caused restriction in supply but exces-
sive demand for reducing equivalents. Therefore, re-
pressed NADH-MR activity in hyperglycemic rats could
be linked to the substantial diversion and utilization of
reducing equivalents to other reductive pathways in ef-
forts to minimize oxidative stress, prompted by erythro-
cyte high ROS content. Thus, the decreased level of
erythrocyte NADH-MR activity of hyperglycemic rats
(Figure 2) is a reflection of a compromised erythrocyte
antioxidant status associated with hyperglycemia
[61,62]. Furthermore, in concordance with the present
reports, Zerez et al., [63] had stated that conditions that
engender decreased erythrocyte NADH content re-
sulted to decreased rate of methaemoglobin reduction
in connection to impaired NADH-MR activity. This
condition is responsible, in part, for relatively high
methaemoglobin content in sickle erythrocytes and sus-
ceptibility to oxidative damage [27]. Based on the
present observations, it is presumed that adjustments in
diabetic erythrocyte methaemoglobin levels might pro-
vide early indication of diabetic antioxidant and oxida-
tive stress status.
Studies suggest that insulin plays a stimulatory role in
Na+/K+-ATPase activity through tyrosine phosphoryl-
ation process [11]. The relatively reduced levels of
erythrocyte Na+/K+-ATPase activity in hyperglycemic
rats (Figure 3) was consistent with the findings of previ-
ous authors. Soulis-Liparota et al., [64] reported reducedNa+/K+-ATPase activity streptozotocin-induced diabetic
rats with nephropathy, whereas, Di Leo et al., [65] and
Kowluru, [66] reported impairment in the enzyme ac-
tivity in diabetic rats and mice with retinopathy. In a
different study, using human participants, Iwalokun
and Iwalokun, [35] noted compromised erythrocyte
Na+/K+-ATPase activity in Type 1 diabetic patients
from Lagos, Nigeria. This finding was corroborated by
Mimura et al., [67] study, in which they noted reduc-
tion of erythrocyte Na+/K+-ATPase activity in Type 2
diabetic patients with hyperkalemia. Raccah et al., [68]
suggested that diabetes-induced Na+/K+-ATPase activ-
ity dysfunction could be implicated in the pathogenesis
of human diabetic neuropathy and the electrophysio-
logical abnormalities.
The findings reported here was in concordance with
those of Konukoglu et al., [69]. They noted that hyper-
cholesterolemia and free radical-induced mechanisms
may be responsible for the inhibition of erythrocyte
Na+/K+-ATPase activity in patients with Type 2 diabetes
mellitus. According to the present study, decreased
erythrocyte Na+/K+-ATPase activity of hyperglycemic
rats was analogous to altered enzyme activity in periph-
eral neurons of individuals with diabetic neuropathy. Ac-
cording to Greene et al., [70], impaired Na+/K+-ATPase
activity is induced by hyperglycemia with characteristic
distortions in myo-inositol and phosphoinositol metabol-
ism, which normalizes with intensive insulin therapy that
controls hyperglycemia [71]. Thus, decreased erythrocyte
Na+/K+-ATPase activity was an obvious confirmation of a
connection between the capacity of erythrocyte to actively
transport Na+/K+ ions (antiport) and obligatory utilization
of ATP for α-subunit of Na+/K+-ATPase phosphorylation
required for enzyme activity [11,13,72]. Hyperglycemia
with associated depressed glucose utilization in diabetic
states results in low intracellular ATP concentration, insuf-
ficient for the required obligatory phosphorylation of the
enzyme. The dose dependent increase in erythrocyte
Na+/K+-ATPase activity in hyperglycemic rat treated with
extract of A. sativa as instrument of glycemic control was
an indication of improve glucose utilization exemplified
in hyperglycemic rats treated with the standard anti-
diabetic drug. The role and mechanism of insulin in
regulation of Na+/K+-ATPase activity has been described
elsewhere [73]. In another study, Konukoglu et al., [69]
reported that hypercholesterolemia and free radical-
induced mechanisms may be responsible for the inhib-
ition of erythrocyte Na+/K+-ATPase activity patients with
type 2 diabetes mellitus.
The present study showed that erythrocyte GST,
NADH-MR and Na+/K+-ATPase activities gave insights
into the pathophysiology of diabetic state and could serve
as a biomarker for ascertaining therapeutic control in
Type 1 diabetes mellitus.
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